Onconic Therapeutics Inc. (KOSDAQ:476060)
South Korea flag South Korea · Delayed Price · Currency is KRW
45,100
+4,350 (10.67%)
Sep 19, 2025, 3:30 PM KST

Onconic Therapeutics Income Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21
29,42514,83821,0569560
Revenue Growth (YoY)
442.96%-29.53%22064.25%58.33%-
Cost of Revenue
4.273.782.3714,9338,402
Gross Profit
29,42114,83521,054-14,838-8,342
Selling, General & Admin
17,9148,0872,463--
Research & Development
9,19210,92915,761--
Other Operating Expenses
134.43164.15138.3--
Operating Expenses
27,71419,63218,823--
Operating Income
1,707-4,7982,231-14,838-8,342
Interest Expense
-15.68-664.16-1,776-1,078-6,831
Interest & Investment Income
1,204942.63863.011,43118.85
Currency Exchange Gain (Loss)
-577.552,020-79.65--
Other Non Operating Income (Expenses)
0.52-7,442-576.0952.865.74
EBT Excluding Unusual Items
2,319-9,942662.51-14,432-15,149
Gain (Loss) on Sale of Assets
---0.7--
Pretax Income
2,319-9,942661.81-14,432-15,149
Income Tax Expense
-2,253-1,849-1,021--
Net Income
4,572-8,0931,682-14,432-15,149
Net Income to Common
4,572-8,0931,682-14,432-15,149
Shares Outstanding (Basic)
108111
Shares Outstanding (Diluted)
108111
Shares Change (YoY)
778.57%960.95%-0.00%0.94%-
EPS (Basic)
450.52-989.812911.00-18726.75-19842.02
EPS (Diluted)
444.29-989.812911.00-18726.75-19842.02
Free Cash Flow
-4,239-7,9822,983-17,536-8,861
Free Cash Flow Per Share
-412.01-976.303870.30-22754.63-11606.95
Gross Margin
99.98%99.98%99.99%--
Operating Margin
5.80%-32.33%10.60%-15618.48%-13903.24%
Profit Margin
15.54%-54.54%7.99%-15191.48%-25247.72%
Free Cash Flow Margin
-14.41%-53.79%14.16%-18458.96%-14769.11%
EBITDA
2,181-4,3452,691-14,770-8,292
EBITDA Margin
7.41%-29.28%12.78%--
D&A For EBITDA
473.54452.67460.1367.4349.65
EBIT
1,707-4,7982,231-14,838-8,342
EBIT Margin
5.80%-32.33%10.60%--
Source: S&P Global Market Intelligence. Standard template. Financial Sources.